1082503-77-2

Usage

Uses

Used in Pharmaceutical Industry:
[1-(2-Hydroxy-2-Methyl-propyl)pyrazol-4-yl]boronic acid pinacol ester is used as a catalyst for facilitating chemical reactions in the synthesis of new pharmaceutical compounds. Its boronic acid pinacol ester group is instrumental in coupling reactions, which are essential for creating novel bonds in drug molecules.
Used in Biotechnology:
In the biotechnology sector, [1-(2-Hydroxy-2-Methyl-propyl)pyrazol-4-yl]boronic acid pinacol ester is employed as a reagent in the development of new biological tools and processes. Its unique structure allows for interactions with various biomolecules, potentially enhancing the efficiency of biotechnological applications.
Used in Catalyst Development:
[1-(2-Hydroxy-2-Methyl-propyl)pyrazol-4-yl]boronic acid pinacol ester is used as a catalyst precursor in the chemical industry, where its properties are harnessed to create new catalysts that can improve the efficiency of industrial processes.
Used in Research and Development:
In academic and research settings, [1-(2-Hydroxy-2-Methyl-propyl)pyrazol-4-yl]boronic acid pinacol ester serves as a valuable compound for studying the effects of its structural components on chemical reactivity and potential applications in various fields. This research can lead to the discovery of new uses and properties of the compound.

Upstream product

• 558-30-5 2-methyl-1,2-epoxypropane 
• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 558-42-9 3-chloro-2-methylpropan-2-ol 

Downstream Products

• 1613300-97-2 3,5-difluoro-4-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]phenol 
• 1613300-99-4 1-{4-[2,6-difluoro-4-(4,4,5,5-tetramethyl-[1,3,2]-dioxaborolan-2-yl)phenyl]pyrazol-1-yl}-2-methylpropan-2-ol 
• 1613300-98-3 3,5-difluoro-4-(1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl)phenyl trifluoromethanesulfonate 

Relevant academic research and scientific papers

Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor

The receptor tyrosine kinase Axl plays important roles in promoting cancer progression, metastasis, and drug resistance and has been identified as a promising target for anticancer therapeutics. We used molecular modeling-assisted structural optimization starting with the low micromolar potency compound 9 to discover compound 13c, a highly potent and orally bioavailable Axl inhibitor. Selectivity profiling showed that 13c could inhibit the well-known oncogenic kinase Met with equal potency to its inhibition of Axl superfamily kinases. Compound 13c significantly inhibited cellular Axl and Met signaling, suppressed Axl- and Met-driven cell proliferation, and restrained Gas6/Axl-mediated cancer cell migration or invasion. Furthermore, 13c exhibited significant antitumor efficacy in Axl-driven and Met-driven tumor xenograft models, causing tumor stasis or regression at well-tolerated doses. All these favorable data make 13c a promising therapeutic candidate for cancer treatment.

AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR

A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.

N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF

An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (I), a preparation method therefor, and a use thereof are disclosed in the application. Each substituent are defined in the specification and claims. The series of compounds of the application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary tumor site metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs.

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES

Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT AND PDFGR

Compounds and compositions useful for treating disorders related to KIT and PDGFR are described herein.

FUSED PYRAZOLE DERIVATIVES AS JAK INHIBITORS

Novel fused pyrazole derivatives of Formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

SUBSTITUTED INDAZOLES AND RELATED HETEROCYCLES

The present invention relates to substituted indazoles and related heterocycles. These compounds are useful for the prevention and/or treatment of hyperproliferative, inflammatory and degenerative disorders and diseases. Thus, this invention is also concerned with the use of the compounds of the present invention for the the prevention and/or treatment of hyperproliferative, inflammatory and degenerative disorders and diseases as well as pharmaceutical composition, medicaments and kits comprising the substituted indazoles and related heterocycles of the present invention and processes for manufacturing those compounds.

COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT

Compounds and compositions useful for treating disorders related to Kit are described herein.

DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

The present invention discloses a novel DGAT1 inhibitor, especially the compound of formula (I) or a pharmaceutically acceptable salt thereof, preparation and pharmaceutical composition thereof, as well as their uses in the preparation of a medicament for the prevention and treatment of Familial hyperchylomicronemia (FCS), obesity, hyperlipoproteinemia or hypertriglyceridemia.